Friday, January 06, 2023 9:15:20 AM
Amazing NASH stock.
$1.20.
$3 in February.
Recent ALGS News
- Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 • GlobeNewswire Inc. • 06/05/2024 06:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/31/2024 08:05:56 PM
- Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 • GlobeNewswire Inc. • 05/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2024 08:02:52 PM
- Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH • GlobeNewswire Inc. • 05/21/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 09:01:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:13:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:05:32 PM
- Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 04/30/2024 08:05:00 PM
- Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study • GlobeNewswire Inc. • 04/25/2024 08:05:00 PM
- Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD • GlobeNewswire Inc. • 04/25/2024 12:00:00 PM
- Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024 • GlobeNewswire Inc. • 04/09/2024 12:00:00 PM
- Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects • GlobeNewswire Inc. • 03/18/2024 12:00:00 PM
- Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/12/2024 08:05:00 PM
- Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024 • GlobeNewswire Inc. • 03/05/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:44:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:42:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 10:35:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 10:33:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 10:31:16 PM
- Aligos Therapeutics To Participate in the Leerink Partners Global Biopharma Conference 2024 • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Aligos Therapeutics to Host KOL Event to Discuss Phase 2a HERALD Study of ALG-055009 in MASH on March 7, 2024 • GlobeNewswire Inc. • 02/20/2024 01:00:00 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM